Literature DB >> 10676852

Analgesic effect of interferon-alpha via mu opioid receptor in the rat.

C L Jiang1, L X Son, C L Lu, Z D You, Y X Wang, L Y Sun, R Y Cui, X Y Liu.   

Abstract

Using the tail-flick induced by electro-stimulation as a pain marker, it was found that pain threshold (PT) was significantly increased after injecting interferon-alpha (IFN alpha) into the lateral ventricle of rats. This effect was dosage-dependent and abolished by monoclonal antibody (McAb) to IFN alpha. Naloxone could inhibit the analgesic effect of IFN alpha, suggesting that the analgesic effect of IFN alpha be related to the opioid receptors. Beta-funaltrexamine (beta-FNA), the mu specific receptor antagonist could completely block the analgesic effect of IFN alpha. The selective delta-opioid receptor antagonist, ICI174,864 and the kappa-opioid receptor antagonist, nor-BNI both failed to prevent the analgesic effect of IFN alpha. IFN alpha could significantly inhibit the production of the cAMP stimulated by forskolin in SK-N-SH cells expressing the mu-opioid receptor, not in NG108-15 cells expressing the delta-opioid receptor uniformly. The results obtained provide further evidence for opioid activity of IFN alpha and suggest that this effect is mediated by central opioid receptors of the mu subtype. The evidence is consistent with the hypothesis that multiple actions of cytokines, such as immunoregulatory and neuroregulatory effects, might be mediated by distinct domains of cytokines interacting with different receptors.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10676852     DOI: 10.1016/s0197-0186(99)00124-2

Source DB:  PubMed          Journal:  Neurochem Int        ISSN: 0197-0186            Impact factor:   3.921


  8 in total

1.  Short small-interfering RNAs produce interferon-α-mediated analgesia.

Authors:  P H Tan; Y J Gao; T Berta; Z Z Xu; R R Ji
Journal:  Br J Anaesth       Date:  2012-02-03       Impact factor: 9.166

2.  Antagonising TLR4-TRIF signalling before or after a low-dose alcohol binge during adolescence prevents alcohol drinking but not seeking behaviour in adulthood.

Authors:  Jonathan Henry W Jacobsen; Femke T Buisman-Pijlman; Sanam Mustafa; Kenner C Rice; Mark R Hutchinson
Journal:  Neuropharmacology       Date:  2017-09-22       Impact factor: 5.250

3.  Neuraxial TNF and IFN-beta co-modulate persistent allodynia in arthritic mice.

Authors:  Sarah A Woller; Cody Ocheltree; Stephanie Y Wong; Anthony Bui; Yuya Fujita; Gilson Gonçalves Dos Santos; Tony L Yaksh; Maripat Corr
Journal:  Brain Behav Immun       Date:  2018-11-19       Impact factor: 7.217

4.  A Potent In Vivo Antitumor Efficacy of Novel Recombinant Type I Interferon.

Authors:  Kang-Jian Zhang; Xiao-Fei Yin; Yuan-Qin Yang; Hui-Ling Li; Yan-Ni Xu; Lie-Yang Chen; Xi-Jun Liu; Su-Jing Yuan; Xian-Long Fang; Jing Xiao; Shuai Wu; Hai-Neng Xu; Liang Chu; Kanstantsin V Katlinski; Yuliya V Katlinskaya; Rong-Bing Guo; Guang-Wen Wei; Da-Cheng Wang; Xin-Yuan Liu; Serge Y Fuchs
Journal:  Clin Cancer Res       Date:  2016-09-28       Impact factor: 12.531

5.  Mechanisms for interferon-α-induced depression and neural stem cell dysfunction.

Authors:  Lian-Shun Zheng; Seiji Hitoshi; Naoko Kaneko; Keizo Takao; Tsuyoshi Miyakawa; Yasuhito Tanaka; Hongjing Xia; Ulrich Kalinke; Koutaro Kudo; Shigenobu Kanba; Kazuhiro Ikenaka; Kazunobu Sawamoto
Journal:  Stem Cell Reports       Date:  2014-06-26       Impact factor: 7.765

6.  Microglial responses to peripheral type 1 interferon.

Authors:  Ernest Aw; Yingying Zhang; Michael Carroll
Journal:  J Neuroinflammation       Date:  2020-11-12       Impact factor: 8.322

Review 7.  Interferons in Pain and Infections: Emerging Roles in Neuro-Immune and Neuro-Glial Interactions.

Authors:  Ping-Heng Tan; Jasmine Ji; Chun-Chang Yeh; Ru-Rong Ji
Journal:  Front Immunol       Date:  2021-11-05       Impact factor: 7.561

8.  Exploratory study for identifying systemic biomarkers that correlate with pain response in patients with intervertebral disc disorders.

Authors:  K T Weber; Shina Satoh; D Olivier Alipui; Justin Virojanapa; Mitchell Levine; Cristina Sison; Shaheda Quraishi; Ona Bloom; Nadeen O Chahine
Journal:  Immunol Res       Date:  2015-12       Impact factor: 2.829

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.